is an illness or health condition for which exposure to airborne toxins, any other hazard, or any other adverse condition resulting from the September 11, 2001, terrorist attacks, based on an examination by a medical professional with experience in treating or diagnosing the health conditions included in the applicable list of WTC-related health conditions, is substantially likely to be a significant factor in aggravating, contributing to, or causing the illness or health condition, as determined under paragraph (2); or

is a mental health condition for which such attacks, based on an examination by a medical professional with experience in treating or diagnosing the health conditions included in the applicable list of WTC-related health conditions, is substantially likely to be a significant factor in aggravating, contributing to, or causing the condition, as determined under paragraph (2); and

with respect to a WTC responder, is provided certification of coverage under subsection (b)(2)(B)(iii); or

with respect to a screening-eligible WTC survivor or certified-eligible WTC survivor, is provided certification of coverage under subsection (b)(2)(B)(iii), as applied under section 300mm–32(a) of this title.

evaluated and characterized through the use of a standardized, population-appropriate questionnaire approved by the Director of the National Institute for Occupational Safety and Health; and

assessed and documented by a medical professional with experience in treating or diagnosing health conditions included on the list of WTC-related health conditions.

assessed through the use of a standardized, population-appropriate medical questionnaire approved by the Director of the National Institute for Occupational Safety and Health and a medical examination; and

diagnosed and documented by a medical professional described in subparagraph (A)(ii).

Interstitial lung diseases.

Chronic respiratory disorder—fumes/vapors.

Asthma.

Reactive airways dysfunction syndrome (RADS).

WTC-exacerbated chronic obstructive pulmonary disease (COPD).

Chronic cough syndrome.

Upper airway hyperreactivity.

Chronic rhinosinusitis.

Chronic nasopharyngitis.

Chronic laryngitis.

Gastroesophageal reflux disorder (GERD).

Sleep apnea exacerbated by or related to a condition described in a previous clause.

Posttraumatic stress disorder (PTSD).

Major depressive disorder.

Panic disorder.

Generalized anxiety disorder.

Anxiety disorder (not otherwise specified).

Depression (not otherwise specified).

Acute stress disorder.

Dysthymic disorder.

Adjustment disorder.

Substance abuse.

Low back pain.

Carpal tunnel syndrome (CTS).

Other musculoskeletal disorders.

request a recommendation of the Advisory Committee;

publish a proposed rule in the Federal Register to add such health condition, in accordance with subparagraph (D);

publish in the Federal Register the Administrator’s determination not to publish such a proposed rule and the basis for such determination; or

publish in the Federal Register a determination that insufficient evidence exists to take action under clauses (i) through (iii).

publish such proposed rule in accordance with section 553 of title 5; and

provide interested parties a period of 30 days after such publication to submit written comments on the proposed rule.

the physician shall promptly transmit such determination to the WTC Program Administrator and provide the Administrator with the medical facts supporting such determination; and

on and after the date of such transmittal and subject to subparagraph (B), the WTC Program shall provide for payment under subsection (c) for medically necessary treatment for such condition.

the physician shall promptly transmit such determination to the WTC Program Administrator and provide the Administrator with the facts supporting such determination; and

the Administrator shall make a determination under subparagraph (B) with respect to such physician’s determination.

the timely review of such a determination by a physician panel with appropriate expertise for the condition and recommendations to the WTC Program Administrator;

not later than 60 days after the date of the transmittal under subparagraph (A)(i), a determination by the WTC Program Administrator on whether or not the condition involved is described in subsection (a)(1)(A) and is medically associated with a WTC-related health condition;

certification in accordance with paragraph (1)(B)(ii) of coverage of such condition if determined to be described in subsection (a)(1)(A) and medically associated with a WTC-related health condition; and

a process for appeals of determinations relating to such conditions.

Subject to subparagraphs (B) and (C), the WTC Program Administrator shall reimburse costs for medically necessary treatment under this subchapter for WTC-related health conditions according to the payment rates that would apply to the provision of such treatment and services by the facility under the Federal Employees Compensation Act.

For treatment not covered under subclause (i) or subparagraph (B), the WTC Program Administrator shall establish by regulation a reimbursement rate for such treatment.

select one or more appropriate vendors through a Federal competitive bid process; and

select the lowest bidder (or bidders) meeting the requirements for providing pharmaceutical benefits for participants in the WTC Program.